Jaren Landen, PhD

Fractional Chief Medical Officer

• A clinical leader with 22 years of global pharmaceutical experience, dedicated to developing new medicines for patients with unmet medical needs, particularly in CNS disorders.
• Leads clinical efforts of portfolio programs, with a particular focus on the CSF1R program as it advances to the clinic.
• Previously, served as the Head of the Early Alzheimer’s Disease clinical group at Biogen, where she led the AD drug development strategy for all aspects of the AD pipeline, including Leqembi.
• Pfizer alumni – advanced the neuroscience clinical development of various assets, including varenicline and Lyrica.
• She earned her Ph.D. in Neuroscience from Emory University and was an adjunct professor of Biotechnology at Northeastern University.